Effect of sucralfate and cimetidine on duodenal ulcer-associated antral gastritis and Campylobacter pylori
- PMID: 2660558
- DOI: 10.1016/0002-9343(89)90159-9
Effect of sucralfate and cimetidine on duodenal ulcer-associated antral gastritis and Campylobacter pylori
Abstract
The course of gastritis and Campylobacter pylori was studied in a single-blind randomized trial comparing cimetidine 200 mg three times a day and 400 mg at night and sucralfate 1 g four times a day orally for four weeks in 140 patients with proved duodenal ulcer. At least two antral biopsies were performed during endoscopy before entry and at the end of four weeks. The activity and the degree of chronic inflammation, as assessed histologically by the degree of infiltration of, respectively, polymorphs and chronic inflammatory cells, were graded blindly by two pathologists as nil, mild, moderate, or severe. The density of C. pylori, as assessed after Warthin-Starry stain, was similarly graded. Ulcer-healing rates were comparable in the cimetidine (73.2 percent) and sucralfate (79.7 percent) groups. Improvement of the activity of gastritis occurred significantly (p less than 0.05) more frequently in the sucralfate (33.3 percent) than in the cimetidine group (18.3 percent), and remained so (p less than 0.05) when only patients with healed ulcer were compared. The density of C. pylori decreased significantly in the sucralfate group after treatment (p less than 0.01) but not in the cimetidine group. The 12-month ulcer relapse rates were significantly (p less than 0.05) lower by life-table analysis in patients healed with sucralfate than in those healed with cimetidine and were unaffected by either the density of Campylobacter in either group or the improvement of the gastritis. It is concluded that sucralfate improves duodenal ulcer-associated antral gastritis and decreases the density of C. pylori, and that factors other than bacterial density and antral gastritis may be responsible for the advantage of sucralfate over cimetidine in ulcer relapse.
Similar articles
-
Histological gastritis in duodenal ulcer: relationship to Campylobacter pylori and effect of ulcer therapy.Am J Gastroenterol. 1988 Mar;83(3):278-82. Am J Gastroenterol. 1988. PMID: 3344730 Clinical Trial.
-
Effect of sucralfate on Helicobacter pylori and severity of gastritis in patients with duodenal ulcer.Scand J Gastroenterol Suppl. 1995;210:85-8. Scand J Gastroenterol Suppl. 1995. PMID: 8578216 Clinical Trial.
-
Persistence of Campylobacter pyloridis despite healing of duodenal ulcer and improvement of accompanying duodenitis and gastritis.Dig Dis Sci. 1987 Nov;32(11):1255-60. doi: 10.1007/BF01296375. Dig Dis Sci. 1987. PMID: 3665680
-
Duodenal ulcer disease: what role does Campylobacter pylori play?Scand J Gastroenterol Suppl. 1989;160:14-8. doi: 10.3109/00365528909091729. Scand J Gastroenterol Suppl. 1989. PMID: 2683020 Review.
-
[Has Campylobacter pylori infection any clinical relevance? Methodologic, epidemiologic and clinical studies].Orv Hetil. 1989 Nov 26;130(48):2563-8. Orv Hetil. 1989. PMID: 2689946 Review. Hungarian.
Cited by
-
Effect of sucralfate on antibiotic therapy for Helicobacter pylori infection in mice.Antimicrob Agents Chemother. 2004 Dec;48(12):4582-8. doi: 10.1128/AAC.48.12.4582-4588.2004. Antimicrob Agents Chemother. 2004. PMID: 15561829 Free PMC article.
-
Does treatment of Helicobacter pylori with antibiotics alone heal duodenal ulcer? A randomised double blind placebo controlled study.Gut. 1997 Jul;41(1):43-8. doi: 10.1136/gut.41.1.43. Gut. 1997. PMID: 9274470 Free PMC article. Clinical Trial.
-
Local cellular and immune response by antral mucosa in patients undergoing treatment for eradication of Helicobacter pylori.Dig Dis Sci. 1993 May;38(5):937-43. doi: 10.1007/BF01295924. Dig Dis Sci. 1993. PMID: 8482195
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical